RxDoctor Payments Data

Julie Tullock

Optometrist · Asheville, NCNPI 1295718609

Payments from drug & device makers

$4,014in general payments, 2019–2025

Across 94 payments — averaging $42.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Vision Care, Inc.$3K
  • Alcon$475
  • Oyster Point Pharma, Inc.$188
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$181
  • Bausch & Lomb Americas Inc.$150
  • Notal Vision, Inc.$134
  • plus $291 from 8 others

What the payments were for

  • Consulting fees$2,02550%
  • Speaking & faculty fees$1343%
  • Food & beverage$1,83746%
  • Education$180%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,014 in reported general payments places this provider in the 85th percentile of 1,326 optometrist providers in North Carolina.

See all optometrist providers in North Carolina

Medicare billing

Part B allowed, 2024
$141,834
Medicare patients
971
Services billed
1,632

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine55$63,587
MieboPerfluorohexyloctane/Pf31$28,517
XdemvyLotilaner12$21,802
TyrvayaVarenicline Tartrate30$21,472
Fluorometholone31$3,023
Latanoprost116$1,330
Prednisolone Acetate12$552
Timolol Maleate40$447
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha41$411
ErythromycinErythromycin Base16$156

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$30$63,58755 claims
Bausch & Lomb Americas Inc.Miebo$150$28,51731 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$112$21,80212 claims
Oyster Point Pharma, Inc.Tyrvaya$188$21,47230 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,326 optometrist providers in North Carolina.

Other optometrist in Asheville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →